Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) ...
October 03 2019 - 8:30AM
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of precisely targeted oncology therapies, today
announced that it will present data from its Phase 1/1b clinical
trial of CPI-006 at the Society for Immunotherapy of Cancer (SITC)
34th Annual Meeting 2019 in National Harbor, Maryland, taking place
November 6-10.
Corvus will present data on CPI-006 in an oral presentation and
two poster sessions:
Oral Presentation: |
Abstract O40: |
Immunobiology and clinical activity of CPI-006, an anti-CD73
antibody with immunomodulating properties in a phase 1/1b trial in
advanced cancers. |
Presenter: |
Jason J. Luke, M.D., FACP,
Director of the Cancer Immunotherapeutics Center, Associate
Professor of Medicine, the University of Pittsburgh Medical Center
and Hillman Cancer Center |
Session Title: |
Session 204:
Immune Checkpoints: Newer Targets and Update on Combinations |
Date and Time: |
Friday, November 8, 2019 from
3:45 pm – 4:00 pm ET |
|
|
Poster
Presentations: |
Poster P125: |
Adenosine and AMP gene expression
profiles predict response to adenosine pathway therapies and
indicate a need for dual blockade of CD73 and A2AR with CD73
inhibitors. |
Presenter: |
Stephen Willingham, PhD, Corvus
Senior Scientist |
Poster Session: |
Biomarkers, Immune Monitoring,
and Novel Technologies |
Date and Time: |
Friday, November 8, 2019 from
7:00 am – 8:00 pm ET |
Location: |
Poster Hall: Prince George AB /
Gaylord National Hotel & Convention Center |
|
|
Poster P434: |
A phase 1/1b study to evaluate
the humanized anti-CD73 antibody, CPI-006, as a single agent, in
combination with CPI-444, and in combination with pembrolizumab in
adult patients with advanced cancers. |
Presenter: |
Mehrdad Mobasher, M.D., Corvus
Vice President and Chief Medical Officer |
Poster Session: |
Clinical Trial in Progress |
Date and Time: |
Saturday, November 9, 2019 from
7:00 am – 8:30 pm ET |
Location: |
Poster Hall: Prince George AB /
Gaylord National Hotel & Convention Center |
About Corvus Pharmaceuticals Corvus
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the development and commercialization of precisely
targeted oncology therapies. Corvus’ lead product candidates are
ciforadenant (CPI-444), a small molecule inhibitor of the A2A
receptor, and CPI-006, a humanized monoclonal antibody directed
against CD73 that exhibits immunomodulatory activity and blockade
of adenosine production. These candidates are being studied in
ongoing Phase 1 and 2 clinical trials in patients with a wide range
of advanced solid tumors. Ciforadenant is being evaluated in a
successive expansion cohort trial examining its activity both as a
single agent and in combination with an anti-PD-L1 antibody.
CPI-006 is being evaluated in a multicenter Phase 1/1b clinical
trial as a single agent, in combination with ciforadenant, and with
pembrolizumab. The Company’s third clinical program, CPI-818, an
oral, small molecule drug that has been shown to selectively
inhibit ITK, is in a multicenter Phase 1/1b clinical trial in
patients with several types of T-cell lymphomas. For more
information, visit www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief
Financial Officer Corvus Pharmaceuticals, Inc. 650-900-4522
LLea@corvuspharma.com
MEDIA CONTACT: Sheryl Seapy W2O pure +1
213-262-9390 sseapy@purecommunications.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Apr 2023 to Apr 2024